Clinical Trials Logo

Inflammatory Myopathy clinical trials

View clinical trials related to Inflammatory Myopathy.

Filter by:

NCT ID: NCT06420154 Not yet recruiting - Systemic Sclerosis Clinical Trials

The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases

Start date: May 27, 2024
Phase: Early Phase 1
Study type: Interventional

This is an investigator-initiated trial to evaluate the safety and efficacy of anti- CD19-CAR-T cells in the relapse or refractory autoimmune diseases.

NCT ID: NCT06379646 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease

Start date: April 22, 2024
Phase: N/A
Study type: Interventional

An exploratory clinical study of the safety and efficacy of YTS109 cell injection in subjects with recurrent/refractory autoimmune disease

NCT ID: NCT06373081 Recruiting - Systemic Sclerosis Clinical Trials

Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease

Start date: April 20, 2024
Phase: N/A
Study type: Interventional

This is an investigator-initiated trial to evaluate the safety and efficacy of anti-CD19-CD3E-CAR-T cells in the relapse or refractory autoimmune diseases.

NCT ID: NCT05982041 Not yet recruiting - Cardiac Disease Clinical Trials

Adult Idiopathic Inflammatory Myopathy With Cardiac Injury

Start date: January 1, 2024
Phase:
Study type: Observational [Patient Registry]

Adult patients with suspected or confirmed idiopathic inflammatory myopathy (IIM) will be recruited. Patients will be approached, consented, have baseline demographics, diagnostics and disease activity measures recorded, and blood taken. The collection of data and biological material will mirror usual clinical practice as far as possible. Subjects will ideally attend further visits at 3, 6 and 12 months to have bloods taken, outcome measures recorded and questionnaires completed.In addition, blood, muscle biopsies and imaging undertaken as part of usual care will also be collected for research purposes to measure a number of biomarkers for the assessment of diagnostic accuracy and clinical utility evaluation. As per usual practice, a muscle biopsy will be performed at baseline, and a further biopsy offered at 6 months to assess treatment response. A magnetic resonance (MR) muscle protocol will also be performed as per usual clinical practice, and a gadolinium-enhanced MR heart scan offered. Both these scans will be repeated at 6-12 months. An existing electronic database entry system will be used for data entry and capture on an anonymised basis.

NCT ID: NCT05859997 Recruiting - Systemic Sclerosis Clinical Trials

Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases

Start date: May 17, 2023
Phase: N/A
Study type: Interventional

This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the relapse or refractory autoimmune diseases of China.

NCT ID: NCT04687111 Active, not recruiting - Hypertension Clinical Trials

Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation

PARABLE
Start date: December 16, 2015
Phase: Phase 2
Study type: Interventional

Sacubitril-valsartan, an Angiotensin Receptor Blocker-Neprilysin Inhibitor (ARNI), currently marketed for the management of heart failure, has been shown to reduce cardiovascular morbidity and mortality in stage C heart failure with reduced ejection fraction. In stage C HFpEF, sacubitril-valsartan has also been shown to reduce left atrial volume index measured using echocardiography over a 9 month timeframe. The PARABLE study investigates the hypothesis that sacubitril-valsartan can provide benefits in terms of left atrial structure and function as well as left ventricular structure and function in asymptomatic (stage A/B HFpEF) patients. This is a prospective, randomised, double-blind, double-dummy, phase II study design. The patient population will have hypertension and/or diabetes together with preserved ejection fraction, elevated natriuretic peptide (NP) and abnormal left atrial volume index (LAVI, > 28 mL/m2).

NCT ID: NCT04530461 Recruiting - Clinical trials for Rheumatoid Arthritis

Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases

Start date: June 1, 2020
Phase:
Study type: Observational

An observational study aiming to assess the serological profile of SARS-Cov2 patients with systemic diseases such as systemic lupus erythematosus, Sjogren syndrome, sarcoidosis, inflammatory myopathies, Behçet's disease, Rheumatoid arthritis and Spondyloarthritis

NCT ID: NCT04237987 Not yet recruiting - Clinical trials for Inflammatory Myopathy

Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy

Start date: January 21, 2020
Phase: Phase 2
Study type: Interventional

This study aims to explore the clinical and immunological efficacy of low-dose Interleukin-2 (IL-2) and cyclosporin a (CSA) on idiopathic inflammatory myopathy (IIM)

NCT ID: NCT04062019 Not yet recruiting - Clinical trials for Inflammatory Myopathy

Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy

Start date: August 30, 2019
Phase: Phase 2
Study type: Interventional

This study aims to explore the clinical and immunological efficacy of low-dose Interleukin-2 (IL-2) on idiopathic inflammatory myopathy (IIM).

NCT ID: NCT03786913 Completed - Clinical trials for Duchenne Muscular Dystrophy

Quantitative Muscle Ultrasound as a Marker of Progression in Children With Muscular Diseases

Start date: March 8, 2016
Phase:
Study type: Observational

The aim of our study is to Assess skeletal muscle structural status in children with inflammatory myositis and Duchenne muscular dystrophy using musculoskeletal ultrasound and to perform a longitudinal follow up of these changes over 2 years and to assess the relation between these findings with clinical parameters, functional scales, biochemical and electromyographic tests.